



Increase of the number of outstanding shares

Croissy-Beaubourg, April 26, 2013 – Theradiag (FR0004197747, ALTER), a company specializing in theranostic and in vitro diagnostics, today announced that 21.098 new ordinary shares issued by THERADIAG, immediately assimilated with the existing ordinary shares, have been listed on the market Alternext Paris since April 19, 2013 within the framework of a free allocation.

- Old number of outstanding shares: 3.824.699
- Number of shares to be listed: 21.098
- New number of outstanding shares: 3.845.797

About Theradiag

Backed by its expertise in the distribution, development and manufacturing of in vitro diagnostic tests, Theradiag innovates and develops theranostic tests (combining treatment and diagnosis) that measure the efficiency of biotherapies in the treatment of autoimmune diseases, cancer and AIDS. Theradiag is thus participating in the development of “customized treatment”, which favors the individualization of treatments, the evaluation of their efficiency and the prevention of drug resistance. Theradiag markets the Lisa-Tracker range (CE marked), which is a comprehensive multiparameter diagnosis solution for patients with autoimmune diseases treated with biotherapies. Theradiag is also developing new diagnostic markers thanks to its microRNA platform, which will allow specific biomarkers to be identified in order to guide therapy and will be first and foremost applied to the treatment of AIDS. The Company is based in Marne-la-Vallée, near Paris, and in Montpellier, and has some 50 employees.

For more information about Theradiag, please visit our website: www.theradiag.com



Theradiag
Investor Relations
Nathalie Trepo
Tél: 01 64 62 10 12
ntrepo@theradiag.com

NewCap.
Financial Communications
and investor relations
Valentine Brouchet /
Pierre Laurent
Tél. : 01 44 71 98 52
theradiag@newcap.fr

Alize RP
Press
Caroline Carmagnol
caroline@alizerp.com
Tél. : 06 64 18 99 59
Christian Berg
christian@alizerp.com
Tél. : 01 42 68 86 41